Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2023.109605 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Gregory L Krauss und 4 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, USA. Electronic address: gkrauss@jhmi.edu. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial, Carbamates, Chlorophenols. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MedVal Scientific Information Services, SK Life Science.
Themen: Patientensicherheit
Abstract (Originalsprache)
OBJECTIVE: Cognitive and psychiatric adverse events in patients with epilepsy are important determinants of therapeutic outcomes and patient quality of life. We assessed the relationship between adjunctive cenobamate treatment and selected cognitive and psychiatric treatment-emergent adverse events (TEAEs) in adults with uncontrolled focal epilepsy. METHODS: This was a retrospective analysis of pooled populations of patients with focal epilepsy from two phase 2, randomized, double-blind clinical trials; two open-label extensions (OLEs) of those trials; and a long-term, open-label, phase 3 safety study. Occurrence of cognitive and psychiatric TEAEs in patients treated with adjunctive cenobamate or placebo during double-blind treatment were evaluated. Exposure-adjusted incidence rates of the cognitive and psychiatric TEAEs, defined as the number of TEAEs per patient-year of treatment, during up to 7 years of long-term adjunctive cenobamate treatment, were determined in the pooled OLE and phase 3 patient populations. RESULTS: The pooled randomized trials resulted in a population of 442 patients treated with cenobamate (100 mg/day: n = 108; 200 mg/day: n = 223; 400 mg/day: n = 111) and 216 placebo-treated patients. The combined open-label studies resulted in pooled populations of cenobamate-treated patients ranging from n = 1690 during Year 1 to n = 103 during Year 7. Among cenobamate-treated (all doses) and placebo-treated patients during double-blind treatment, cognitive TEAEs were reported by ≤ 1.9 % (range, 0 %-1.9 %) and ≤ 0.5 % (range, 0 %-0.5 %), respectively, and psychiatric TEAEs by ≤ 3.6 % (range, 0 %-3.6 %) and ≤ 3.2 % (range, 0 %-3.2 %), respectively. During up to 7 years of open-label adjunctive cenobamate treatment, exposure-adjusted incidence rates of cognitive and psychiatric TEAEs were < 0.018 and < 0.038 events per patient-year, respectively. Discontinuation of adjunctive cenobamate due to cognitive or psychiatric TEAEs assessed in this study during double-blind or open-label treatment occurred in ≤ 0.3 % and ≤ 1.7 % of patients, respectively. CONCLUSIONS: Cognitive and psychiatric TEAEs were reported by similar numbers of cenobamate- and placebo-treated patients during double-blind adjunctive cenobamate treatment (< 4 % of patients), and exposure-adjusted incidence rates of these TEAEs remained low during open-label cenobamate treatment for up to 7 years. Treatment discontinuations due to these TEAEs were rare. The results of this post-hoc analysis indicate that adjunctive cenobamate treatment exhibits a low incidence of cognitive or psychiatric TEAEs in patients with uncontrolled focal seizures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, USA. Electronic address: gkrauss@jhmi.edu.
- Neuroscience Institute, Banner-University Medical Center, 755 East McDowell Road, Phoenix, AZ 85006. Electronic address: steve.chung@bannerhealth.com.
- SK Life Science, Inc., 461 From Road, Fifth Floor, Paramus, NJ 07652, USA. Electronic address: lferrari@sklsi.com.
- SK Life Science, Inc., 461 From Road, Fifth Floor, Paramus, NJ 07652, USA. Electronic address: sstern@sklsi.com.
- Comprehensive Epilepsy Care Center for Children and Adults, 11134 Conway Road, St. Louis, MO 63131, USA. Electronic address: werosenfeldmd@gmail.com.
Förderung
- MedVal Scientific Information Services
- SK Life Science
Zitieren
APA
Krauss, G. L., Chung, S. S., Ferrari, L., Stern, S., & Rosenfeld, W. E. (2024). Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2023.109605
Vancouver
Krauss GL, Chung SS, Ferrari L, Stern S, Rosenfeld WE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2023.109605
BibTeX
@article{Krauss2024,
author = {Krauss, Gregory L and Chung, Steve S and Ferrari, Louis and Stern, Sean and Rosenfeld, William E},
title = {Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2023.109605}
}
EUVIMED